Danish biotechnology company NeuroSearch A/S (CPH:NEUR) confirmed on Thursday that it is in discussions with regard to the potential sale of its rights to Pridopidine for a small seven figure amount in DKK.
This is with reference to the article in MedWatch on 19 April 2018 relating to Teva giving up the development of the investigational medicinal product, Pridopidine.
NeuroSearch added that it is still investigating the potential sale of the company, but there is no certainty that these investigations will result in such a sale.
NeuroSearch will provide further information if and when required to do so.
Neurosearch specialises in pharmaceuticals for treating diseases and disorders affecting the central nervous system.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference